Comparing and weighing the different research results, biologics used for psoriasis have not established the ability to lower cardiovascular (CV) risk . Vigorously screening for CV risk factors seems to be the appropriate management for now.
Can the treatment of psoriasis directly impact the CV risk of patients? This is the question that Prof. Joel Gelfand (University of Pennsylvania, USA) strove to answer in his talk, explaining the different possible methods of research and their results.
Patients with psoriasis have an increased risk of mortality and major CV events (MACE), especially when their psoriasis is moderate to severe. Chronic inflammatory, metabolic irregularities, and CV disease are often present in psoriasis. Prof. Gelfand’s lab followed 8,760 psoriasis patients and 87,600 adults without psoriasis over an average time of >4 years . After adjusting for comorbidities, a psoriasis body surface area (BSA) >10% entailed an increased ...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« A new topical PDE-4 inhibitor effective in psoriasis Next Article
Psoriasis therapy for children and pregnancies »
Table of Contents: AAD 2020
Psoriasis – What Is Hot?
Systemic Therapies for Dermatologists
Hidradenitis Suppurativa/Acne Inversa
Pearls of the Posters
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.